Home > A. Molecular pathology > Targeted therapy > Small molecules > tofacitinib
tofacitinib
Wednesday 14 June 2017
Xeljanz Jakvinus
| WKP |
Tofacitinib (INN) is a janus kinase (JAK ) inhibitor class, discovered and developed by the National Institutes of Health and Pfizer. Tofacitinib is marketed as Xeljanz and Jakvinus.
It is currently approved for the treatment of rheumatoid arthritis (RA) in the United States and other countries.
It has demonstrated effectiveness in the treatment of psoriasis in Phase 3 studies. It is being studied for treatment of inflammatory bowel disease, and other immunological diseases, as well as for the prevention of organ transplant rejection.
